High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems

2020

Alzheimer’s disease (AD) has become a significant public health problem, but there is currently no cure for the disease. We pioneered a novel three-dimensional (3D) Alzheimer’s in a Dish model that can revolutionize AD drug screening. This ongoing project will identify and validate novel AD drug candidates using our 3D AD cellular model as a drug screening platform. We will continue to validate and identify AD drug candidates from natural products and microglial-modulating drugs in this period. This year, we will start a pilot drug screening to identify neuroprotective drugs against pathogenic amyloid accumulation and oxidative stress. This study’s goal is to find novel AD drug candidates directly applicable to human clinical trials.


Funding to Date

$230,000

Focus

Drug Discovery, Genes to Therapies™

Researchers

Doo Yeon Kim, Ph.D.


Luisa Quinti, Ph.D.